The trials had been evaluating NX-1207 for use in treating Benign Prostatic Hyperplasia (“BPH”), otherwise known as an enlarged prostate. Much of the share price strength had been due to a stream of positive press releases from Nymox touting the strong prospects for NX-1207. Examples of ...